Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib (Q39348852)

11 September 2017

Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib (English)

1 reference

11 September 2017

1 reference

Aiping Zhou

1

1 reference

11 September 2017

Wen Zhang

2

1 reference

11 September 2017

Chunxiao Chang

3

1 reference

11 September 2017

Xiaoyan Chen

4

1 reference

11 September 2017

Dafang Zhong

5

1 reference

11 September 2017

Qiong Qin

6

1 reference

11 September 2017

Donghua Lou

7

1 reference

11 September 2017

Haoyuan Jiang

8

1 reference

11 September 2017

Jinwan Wang

9

1 reference

11 September 2017

17 September 2013

1 reference

Cancer Chemotherapy and Pharmacology

11 September 2017

1 reference

11 September 2017

72

1 reference

11 September 2017

5

1 reference

11 September 2017

1043-1053

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-013-2282-y

11 September 2017

0 references

cites work

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Modified Fibonacci search.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2282-Y

10.1007/S00280-013-2282-Y

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference